Boone Capital Management’s Tenax Therapeutics TENX Stock Holding History

Boone Capital Management’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.2M	Buy	+200,000	New	+$2.71M	0.98%	13

Other funds holding TENX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boone Capital Management's TENX Position: Q1 2026 in Review

Boone Capital Management opened a new position in Tenax Therapeutics (TENX) in Q1 2026: 200,000 shares worth $3.2M. The stake represents 0.98% of the portfolio and ranks #13 among its holdings.

80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

Boone Capital Management held 200,000 shares of Tenax Therapeutics worth $3.2M as of Q1 2026.
Tenax Therapeutics was a new Boone Capital Management position in Q1 2026.
Tenax Therapeutics made up 0.98% of Boone Capital Management's portfolio in Q1 2026, its #13 holding.
80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Boone Capital Management's 13F filing for Q1 2026, filed 15 May 2026.